Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine UCSF
Dates
study started
completion around
Principal Investigator
by Hope Rugo (ucsf)
Headshot of Hope Rugo
Hope Rugo

Description

Summary

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

Official Title

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

Keywords

Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer, Breast Neoplasms, Endometrial Neoplasms, Trastuzumab, Pertuzumab, Everolimus, Aromatase Inhibitors, Abemaciclib, Alpelisib, Aromatase Inhibitor (AI)

Eligibility

Locations

  • University of California, Irvine
    Orange California 92868 United States
  • UCSF Medical Center at Mission Bay
    San Francisco California 94158 United States
  • Beverly Hills Cancer Center
    Beverly Hills California 90211 United States

Lead Scientist at University of California Health

  • Hope Rugo (ucsf)
    Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer
ID
NCT04188548
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 500 study participants
Last Updated